"...So Yale gets 240mil shares up to phase1b/11."
Yale University isn't to receive 240m shares in VHL, Tylemahos.
Rather the shares - equal to 30pc of expanded VHL capital - will be owned by shareholders in Pathway Oncology Pty Ltd, a Brisbane-based shell controlled by venture capitalist and VHL director-elect, Paul Hopper.
As I understand it, VHL will acquire Pathway and Pathway, as a Virax subsidiary, will be liable to pay Yale monies - yet to be disclosed - under the licensing deal apparently negotiated by Hopper.
These deals will need to be placed before shareholders.
Some will apply careful scrutiny before ratifying.
"...So Yale gets 240mil shares up to phase1b/11."Yale University...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.001(3.57%) |
Mkt cap ! $46.40M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.8¢ | 2.7¢ | $2.318K | 83.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 504704 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 2243930 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| VHL (ASX) Chart |